Ghrelin / GHS-R agonism → GH pulse · Peptide
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
Five 15-minute IV infusion levels, eight healthy male volunteers per level: terminal half-life approximately 2 hours and GH peak around 0.67 hours.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: No established general treatment protocol; retain the population, molecule and route limitations.
Open this exact record in the library →Suggest a correctionDistinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Proposed combination; product formulation unspecified
Attributed proposal / anecdote: Amount: Approximately 600 mcg tesamorelin + 200 mcg ipamorelin; Route: Not documented; Formulation: Proposed combination; product formulation unspecified
Limitations: Dose attribution only. Frequency, route and duration are not supplied for this combination passage. Equivalence to HGH, muscle superiority and safety are unproven.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: CJC no-DAC / Mod GRF(1-29) with ipamorelin
Attributed proposal / anecdote: Amount: Approximately 100 mcg CJC no-DAC + 150–250 mcg ipamorelin; Frequency: Optional five days on / two days off; Timing: Fasted 90–120 minutes after food; commonly pre-bed; optional fasted morning use; Route: SC; Formulation: CJC no-DAC / Mod GRF(1-29) with ipamorelin
Limitations: Retained from the field-guide synthesis; original clinic/source identifier is not supplied. Not a validated clinical combination protocol.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Route: Not documented; Sequence: Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns
Limitations: No amount, duration, route, phase interval or CJC DAC status is supplied. Association with this no-DAC listing does not establish that the video used no-DAC.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.